Abstract
Carcinoma of unknown primary site remains a common clinical diagnosis. accounting for between 5 and 10% of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0-48%. We present the results of a single centre phase II study of the use of the combination of mitomycin C (7 m m(-2) on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m(-2) on day 1) and continuous infusion 5-fluorouracil (300 mg m(-2) daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Infirmary between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient), Toxicity was acceptable, with 1958 grade 3 or 4 neutropenia, 16% grade 3 or 4 thrombocytopenia and 13% grade 3 or 4 nausea and vomiting. No cases of neutropenic sepsis were seen and there, were no treatment-related deaths, however, six patients developed thrombotic complications. The over-all response rate was 27% (CR 3% PR 21396). Median time to progression was 3.4 months (95% CI 1.1.-5.6 months) and median overall survival was 7.7 months (95% CI 5.7-9.8 months). Survival at I year was 28%, and at 2,ears, 10% MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease. (C) 2002 Cancer Research UK.
| Original language | English |
|---|---|
| Pages (from-to) | 1238-1242 |
| Number of pages | 4 |
| Journal | British Journal of Cancer |
| Volume | 86 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2002 |
Keywords
- MCF
- adenocarcinoma
- carcinoma of unknown primary site
- METASTATIC ADENOCARCINOMA
- CHEMOTHERAPY
- CARBOPLATIN
- ORIGIN
- CANCER
- TRIAL
- DOXORUBICIN
- PACLITAXEL
- ETOPOSIDE
- CYCLOPHOSPHAMIDE
Cite this
A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. / MacDonald, Alistar Gordon; Nicolson, M. C.; Samuel, Leslie; Hutcheon, A. W.; Ahmed, Fazle.
In: British Journal of Cancer, Vol. 86, No. 8, 2002, p. 1238-1242.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site
AU - MacDonald, Alistar Gordon
AU - Nicolson, M. C.
AU - Samuel, Leslie
AU - Hutcheon, A. W.
AU - Ahmed, Fazle
PY - 2002
Y1 - 2002
N2 - Carcinoma of unknown primary site remains a common clinical diagnosis. accounting for between 5 and 10% of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0-48%. We present the results of a single centre phase II study of the use of the combination of mitomycin C (7 m m(-2) on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m(-2) on day 1) and continuous infusion 5-fluorouracil (300 mg m(-2) daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Infirmary between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient), Toxicity was acceptable, with 1958 grade 3 or 4 neutropenia, 16% grade 3 or 4 thrombocytopenia and 13% grade 3 or 4 nausea and vomiting. No cases of neutropenic sepsis were seen and there, were no treatment-related deaths, however, six patients developed thrombotic complications. The over-all response rate was 27% (CR 3% PR 21396). Median time to progression was 3.4 months (95% CI 1.1.-5.6 months) and median overall survival was 7.7 months (95% CI 5.7-9.8 months). Survival at I year was 28%, and at 2,ears, 10% MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease. (C) 2002 Cancer Research UK.
AB - Carcinoma of unknown primary site remains a common clinical diagnosis. accounting for between 5 and 10% of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0-48%. We present the results of a single centre phase II study of the use of the combination of mitomycin C (7 m m(-2) on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m(-2) on day 1) and continuous infusion 5-fluorouracil (300 mg m(-2) daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Infirmary between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient), Toxicity was acceptable, with 1958 grade 3 or 4 neutropenia, 16% grade 3 or 4 thrombocytopenia and 13% grade 3 or 4 nausea and vomiting. No cases of neutropenic sepsis were seen and there, were no treatment-related deaths, however, six patients developed thrombotic complications. The over-all response rate was 27% (CR 3% PR 21396). Median time to progression was 3.4 months (95% CI 1.1.-5.6 months) and median overall survival was 7.7 months (95% CI 5.7-9.8 months). Survival at I year was 28%, and at 2,ears, 10% MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease. (C) 2002 Cancer Research UK.
KW - MCF
KW - adenocarcinoma
KW - carcinoma of unknown primary site
KW - METASTATIC ADENOCARCINOMA
KW - CHEMOTHERAPY
KW - CARBOPLATIN
KW - ORIGIN
KW - CANCER
KW - TRIAL
KW - DOXORUBICIN
KW - PACLITAXEL
KW - ETOPOSIDE
KW - CYCLOPHOSPHAMIDE
U2 - 10.1038/sj.bjc.6600258
DO - 10.1038/sj.bjc.6600258
M3 - Article
VL - 86
SP - 1238
EP - 1242
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 8
ER -